We have developed and manufactured MOLISAN since 2006. Our products bring together years of work, practical experience and feedback from the people who use them. Explore the laboratory studies and documents for our products.
Antiseptic effectiveness — NCDC study, 2026
In a study by Georgia’s National Center for Disease Control, ready-to-use MOLISAN demonstrated full effectiveness after 15 minutes of exposure for antiseptic preparation of surgical and injection areas of the skin. The result is stated in the official letter dated 4 September 2026, No. NCDC 9 26 01181701.
The laboratory report for sample 26CO414840 records No Growth for P. aeruginosa ATCC 27853, E. hirae ATCC 10541 and S. aureus ATCC 25923.
View the conclusion and results
Tbilisi State Medical University studies
In 2015–2016, Tbilisi State Medical University conducted preclinical general-toxicity studies of MOLISAN, MOLISAN ELIXIR and MOLISAN LOTION. Each document identifies the product studied, the year and the composition used in the study.
The 2016 preclinical study of MOLISAN LOTION found no acute toxicity, allergenicity or local irritation from external application of the tested preparation in white mice. Document
The 2016 preclinical study of MOLISAN ELIXIR found no acute toxic, cumulative, locally irritating or allergic effects of the tested preparation in laboratory animals. Document
The 2015 preclinical study of MOLISAN found no acute toxic, cumulative, locally irritating or allergic effects of the tested preparation in laboratory animals. Document
Laboratory reports and certificates
Our collection includes laboratory reports, a declaration of conformity and GLOBALTEST certificates from different years. Each document lists its product, issue date and validity period where one is specified.
Quality and product use
Composition, directions and storage information help you choose and use the right product.